"Efficacy of SGLT2 inhibitors in non-diabetic non-alcoholic fatty liver disease: a systematic review and meta-analysis".

J Diabetes Metab Disord · 2025 · PMC12678672 · PMID 41358327

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

showed a trendP = 0.06so close (0.05 < p ≤ 0.1)

Notably, GGT showed a trend favoring SGLT2i with a borderline p-value ( P = 0.06 in the anti-diabetic drug subgroup), while FBG reduction lacked statistical significance.

also in 33,481 other papers

a favorable trendno p-value reported

Overall, SGLT2i showed a superior profile in terms of anthropometric outcomes and liver enzyme improvement, with a favorable trend across most markers, particularly in the placebo subgroup, reinforcing their potential role in metabolic dysfunction-associated conditions like MASLD/NASH.

also in 1,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.